xeruborbactam   Click here for help

GtoPdb Ligand ID: 13131

Synonyms: QPX7728
PDB Ligand
Compound class: Synthetic organic
Comment: Xeruborbactam is a bicyclic boronate β-lactamase inhibitor (BLI) with a broad-spectrum of activity against both serine and metallo-β-lactamases [1]. Xeruborbactam is under clinical evaluation and was developed as a continuation of the program that discovered vaborbactam, with the aim of expanding the spectrum of activity to allow treatment of infections caused by a wider range of pathogens.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 66.76
Molecular weight 221.98
XLogP 0.43
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=C2[C@H]3C[C@H]3B(O)OC2=C(C(=C1)F)C(=O)O
Isomeric SMILES B1([C@@H]2C[C@@H]2C3=C(O1)C(=C(C=C3)F)C(=O)O)O
InChI InChI=1S/C10H8BFO4/c12-7-2-1-4-5-3-6(5)11(15)16-9(4)8(7)10(13)14/h1-2,5-6,15H,3H2,(H,13,14)/t5-,6-/m1/s1
InChI Key KOHUFVUIYUCFNG-PHDIDXHHSA-N
No information available.
Summary of Clinical Use Click here for help
An intravenously administered combination of xeruborbactam and QPX2014 (an undisclosed β-lactam antibacterial), has completed two Phase 1 trials (NCT04380207 and NCT05072444). This drug combination is being developed by Qpex Biopharma (registered trademark OMNIvance®) as a treatment for serious infections caused by drug-resistant strains of Acinetobacter, Pseudomonas and Enterobacterales.
QPX7831, an orally bioavailable xeruborbactam prodrug, is also under clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04380207 P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV Phase 1 Interventional Qpex Biopharma, Inc.
NCT05072444 Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects Phase 1 Interventional Qpex Biopharma, Inc.